Company intelligence / Profile preview
OncoQR ML
Vienna, Austriaoncoqr.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
OncoQR ML has demonstrated in vivo proof of concept for its lead candidates targeting G17 and HER2/neu. The S-TIR™ platform enables the activation of all four natural tumor-killing immune mechanisms in a tumor-specific manner. Lead programs have shown robust immune responses and preclinical efficacy in animal models; no clinical data reported yet.
- Therapeutic areas
- Oncology
- Modalities
- VaccineBiologic (platform-based cancer immunotherapy)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
TYG Oncology Ltd. (joint venture for hormone neutralization therapies and co-development of TYG100/OQR100)
Beyond the preview
Go deeper on OncoQR ML.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OncoQR ML.